Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

3 Healthcare Innovators With Game-Changing Treatments

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, rising R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks, Eli Lilly (LLY), Bristol-Myers (BMY), and Merck & Co. (MRK), which look poised for blockbuster…

StockNews.com

3 Leading S&P 500 Stocks Set to Climb Even Higher

As the stock market evolves, leading S&P 500 stocks like Eli Lilly and Company (LLY), Howmet Aerospace (HWM), and NetApp (NTAP) are well-positioned to capitalize on current market conditions and climb higher. Read on….

StockNews.com

Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss

Roche is working on bringing its weight-loss medications to patients "faster than anticipated,” making it yet another contender in the weight-loss drug market.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Jim Cramer Names Six Companies That May Enter the Trillion-Dollar Stock Club

In a recent episode of CNBC's Mad Money show, Jim Cramer named companies like Eli Lilly, Tesla, JPMorgan, and Walmart that could reach a $1 trillion market valuation.

International Business Times UK

NBCU Plans Commercial-Free Hour During Olympic Opening Ceremonies

Coca-Cola, Delta, Eli Lilly, Toyota, Visa, Xfinity get ‘brought to you by’ mentions

Broadcasting & Cable

What You Need to Know Ahead of Eli Lilly's Earnings Release

As Eli Lilly gears up to release its second-quarter earnings next month, analysts project a double-digit bottom-line growth.

Barchart

These weight-loss startups tell customers they can stop taking Ozempic or Wegovy and stay thin. Doctors disagree

As nearly $1 billion of venture capital dollars have been injected into weight-loss startups since 2023, companies are making unproven claims to attract customers. It’s a new twist on a story as old as the diet industry.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Weight Loss Drug Beats Ozempic In Head-to-head Study

Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.

International Business Times

Ozempic maker slams Biden after the president accused the drug company of ‘ripping off’ US consumers

Remarks came after the president and Senator Bernie Sanders blasted the pharmaceutical giant for its ‘unconscionably high prices’

The Independent UK

What Is Kisunla? Know All About New FDA-Approved Drug For Alzheimer's Disease

Kisunla manufactured by Eli Lilly could significantly slow cognitive decline in people with early symptomatic Alzheimer's disease, according to results of the company's clinical trials.

Medical Daily

FDA Approves New Alzheimer's Drug To Slow Disease Progression

FDA approves Eli Lilly's donanemab for early Alzheimer's, offering hope for patients and caregivers. Treatment priced at 5 per vial.

Top News

FDA approves second Alzheimer’s drug that can slow onset of disease

Eli Lilly says Kisunla demonstrated ‘meaningful results’ for people showing early symptoms of the disease

The Guardian - US

Biden Calls For Lower Prices Of Ozempic, Similar Drugs

US President Joe Biden on Tuesday called on pharmaceutical giants Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs such as Ozempic, saying firms must stop "ripping off the American people."

International Business Times

3 Mega-Cap Stocks to Consider Before They're Worth $1 Trillion

Mega-cap stocks are the flavor of the season, and these three big names are the next set of contenders racing towards the $1 trillion market cap club.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Chart of the Day: Eli Lilly - More New Highs

Author's Note: Last featured 10/26/23 at $586.37. Gained 54% since that date. The Chart of the Day belongs to the drug manufacturer Eli Lilly (LLY) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current...

Fortune

Novo Nordisk’s Wegovy may just have two years to take over China’s market for weight loss drugs

Novo Nordisk's China patent on Wegovy's active ingredient expires in 2026, much earlier than its patents in the U.S., Japan and Europe.

The Guardian - UK

Ozempic maker Novo Nordisk invests $4bn to meet US ‘skinny jab’ demand

Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product Wegovy

The Conversation

Lawsuit could challenge trust in Ozempic and other popular weight loss drugs

The manufacturers of the most popular weight loss drugs are being challenged in court.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

3 Stocks Most Likely to Join the $1 Trillion Market Cap Club in the Next 5 Years

With a solid product portfolio, brand strength, and a thirst for innovation, these three companies are on the right track.

The Independent UK

Alzheimer's drug that can slow disease gets backing from FDA advisers

Federal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia

Barchart

Structure Therapeutics vs. Viking Therapeutics: Which Weight-Loss Drug Stock Wins?

With weight-loss drugs gaining traction, which biopharma stock wins?

Barchart

Eli Lilly Stock: Is LLY Outperforming the Healthcare Sector?

Eli Lilly has outperformed the healthcare sector over the past three months, but analysts remain cautiously optimistic about the stock’s prospects.

Al Jazeera

In China, weight-loss drugs are becoming big business

Chinese pharmaceutical companies are racing to roll out weight-loss drugs amid the popularity of Ozempic.

StockNews.com

3 Pharma Stocks Poised for Big Returns This Summer

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs and the incorporation of cutting-edge technologies into drug manufacturing. Hence, pharma stocks Eli Lilly (LLY), Green Thumb Industries (GTBIF), and Supernus Pharmaceuticals (SUPN) might be worth buying for returns this summer. Read more….

Barchart

Do Wall Street Analysts Like Eli Lilly Stock?

Eli Lilly stock has outperformed the broader market over the past year, and Wall Street analysts remain optimistic about the stock’s prospect.

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.